Virus Entry Inhibitors: Past, Present, and Future

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2022 Apr 12

PMID 35412131

Authors

Shan Su

Wei Xu

Shibo Jiang

Affiliations

Soon will be listed here.

Abstract

The approval of enfuvirtide marked a milestone for the development of virus entry inhibitor-based antiviral therapeutics. Since then, more peptide-, small-molecule-, and protein-based entry inhibitors have been identified and approved for viral diseases. Here we reviewed the development of virus entry inhibitors and the advantages and disadvantages of peptide-, small-molecule-, and protein-based entry inhibitors, herein summarizing the future trend of these antivirals. Virus entry inhibitors take effect outside the host cell, making them good candidates for development as pre- and post-exposure prophylaxis, microbicides, and therapeutics. This chapter, as well as this book, provides more information on the development and modification of peptide-, small-molecule-, and protein-based virus entry inhibitors.

Citing Articles

Plant Cell-Engineered Gold Nanoparticles Conjugated to Quercetin Inhibit SARS-CoV-2 and HSV-1 Entry.

Elste J, Kumari S, Sharma N, Razo E, Azhar E, Gao F Int J Mol Sci. 2023; 24(19).

PMID: 37834240 PMC: 10573121. DOI: 10.3390/ijms241914792.

References

Anantpadma M, Kouznetsova J, Wang H, Huang R, Kolokoltsov A, Guha R . Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors. Antimicrob Agents Chemother. 2016; 60(8):4471-81. PMC: 4958205. DOI: 10.1128/AAC.00543-16. View

Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F . IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog. 2019; 15(12):e1008082. PMC: 6894747. DOI: 10.1371/journal.ppat.1008082. View

Boulware D, Pullen M, Bangdiwala A, Pastick K, Lofgren S, Okafor E . A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 383(6):517-525. PMC: 7289276. DOI: 10.1056/NEJMoa2016638. View

Boyd M, Gustafson K, McMahon J, Shoemaker R, OKeefe B, Mori T . Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother. 1997; 41(7):1521-30. PMC: 163952. DOI: 10.1128/AAC.41.7.1521. View

Chan D, Fass D, Berger J, Kim P . Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997; 89(2):263-73. DOI: 10.1016/s0092-8674(00)80205-6. View

Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q . Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol. 2011; 85(18):9395-405. PMC: 3165761. DOI: 10.1128/JVI.05119-11. View

Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J . Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol. 2013; 88(2):1125-39. PMC: 3911630. DOI: 10.1128/JVI.02566-13. View

Cocchi F, Devico A, Garzino-Demo A, Arya S, Gallo R, Lusso P . Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270(5243):1811-5. DOI: 10.1126/science.270.5243.1811. View

Curreli F, Ahmed S, Benedict Victor S, Iusupov I, Belov D, Markov P . Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. J Med Chem. 2020; 63(4):1724-1749. PMC: 7703574. DOI: 10.1021/acs.jmedchem.9b02149. View

10.

Debnath A, RADIGAN L, Jiang S . Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem. 1999; 42(17):3203-9. DOI: 10.1021/jm990154t. View

11.

Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-Ul-Hussan S . Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem. 2012; 287(18):15076-86. PMC: 3340262. DOI: 10.1074/jbc.M111.332361. View

12.

Drucker D . Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2019; 19(4):277-289. DOI: 10.1038/s41573-019-0053-0. View

13.

Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S . Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018; 379(7):645-654. DOI: 10.1056/NEJMoa1711460. View

14.

Forssmann W, The Y, Stoll M, Adermann K, Albrecht U, Tillmann H . Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med. 2010; 2(63):63re3. DOI: 10.1126/scitranslmed.3001697. View

15.

Guo L, Bi W, Wang X, Xu W, Yan R, Zhang Y . Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2020; 31(1):98-100. PMC: 7656503. DOI: 10.1038/s41422-020-00438-w. View

16.

He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X . Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem. 2008; 283(17):11126-34. DOI: 10.1074/jbc.M800200200. View

17.

Hendrix C, Collier A, Lederman M, Schols D, Pollard R, Brown S . Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37(2):1253-62. DOI: 10.1097/01.qai.0000137371.80695.ef. View

18.

Lee I, Palombo M, Zhang X, Szekely Z, Sinko P . Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery. Eur J Pharm Biopharm. 2018; 138:11-22. PMC: 6286870. DOI: 10.1016/j.ejpb.2018.06.004. View

19.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

20.

Holthausen D, Lee S, Kumar V, Bouvier N, Krammer F, Ellebedy A . An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses. Immunity. 2017; 46(4):587-595. DOI: 10.1016/j.immuni.2017.03.018. View